CONTEXT: A relationship between primary hyperparathyroidism (PHPT) and obesity has been observed but is incompletely understood. Furthermore, obesity has been associated with vitamin D deficiency, suggesting that the three conditions may be linked. OBJECTIVE: We hypothesized that PHPT in morbidly obese patients is more severe and that the difference may be explained by vitamin D deficiency. DESIGN AND SETTING, PARTICIPANTS, AND OUTCOME MEASURES: Records of 196 patients with surgically treated PHPT and known body mass index (BMI) were examined. Patients were stratified into three BMI groups: group I (nonobese), BMI < 25 kg/m(2) (n = 54); group II (non-severely obese), BMI 25-34 kg/m(2) (n = 102); and group III (severely obese), BMI 35 kg/m(2) or greater (n = 40). RESULTS: Preoperative PTH levels were higher in group ΙΙΙ compared with group Ι (181 ± 153 vs. 140 ± 80 pg/ml, p = 0.04). Group III patients had larger tumors on average compared with group I (1.8 ± 1.5 vs. 1.04 ± 1.5 g, P = 0.0002). In group III, BMI positively correlated with parathyroid tumor weight (r = 0.5, P = 0.002). Postoperative PTH was higher in group III compared with group Ι (61 ± 41 vs. 44 ± 28 pg/ml, P = 0.02). There was higher frequency of depression, musculoskeletal symptoms, weakness, and gastroesophageal reflux disease in group III patients. CONCLUSIONS: BMI positively correlated with parathyroid tumor weight independent of vitamin D. Severely obese patients have larger parathyroid tumor weight, higher pre- and postoperative PTH, and greater symptoms.
CONTEXT: A relationship between primary hyperparathyroidism (PHPT) and obesity has been observed but is incompletely understood. Furthermore, obesity has been associated with vitamin D deficiency, suggesting that the three conditions may be linked. OBJECTIVE: We hypothesized that PHPT in morbidly obesepatients is more severe and that the difference may be explained by vitamin D deficiency. DESIGN AND SETTING, PARTICIPANTS, AND OUTCOME MEASURES: Records of 196 patients with surgically treated PHPT and known body mass index (BMI) were examined. Patients were stratified into three BMI groups: group I (nonobese), BMI < 25 kg/m(2) (n = 54); group II (non-severely obese), BMI 25-34 kg/m(2) (n = 102); and group III (severely obese), BMI 35 kg/m(2) or greater (n = 40). RESULTS: Preoperative PTH levels were higher in group ΙΙΙ compared with group Ι (181 ± 153 vs. 140 ± 80 pg/ml, p = 0.04). Group III patients had larger tumors on average compared with group I (1.8 ± 1.5 vs. 1.04 ± 1.5 g, P = 0.0002). In group III, BMI positively correlated with parathyroid tumor weight (r = 0.5, P = 0.002). Postoperative PTH was higher in group III compared with group Ι (61 ± 41 vs. 44 ± 28 pg/ml, P = 0.02). There was higher frequency of depression, musculoskeletal symptoms, weakness, and gastroesophageal reflux disease in group III patients. CONCLUSIONS: BMI positively correlated with parathyroid tumor weight independent of vitamin D. Severely obesepatients have larger parathyroid tumor weight, higher pre- and postoperative PTH, and greater symptoms.
Authors: John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells Journal: J Clin Endocrinol Metab Date: 2002-12 Impact factor: 5.958
Authors: D S Rao; M Honasoge; G W Divine; E R Phillips; M W Lee; M R Ansari; G B Talpos; A M Parfitt Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Georges Saab; Adam Whaley-Connell; Samy I McFarlane; Suying Li; Shu-Cheng Chen; James R Sowers; Peter A McCullough; George L Bakris Journal: Metabolism Date: 2009-10-02 Impact factor: 8.694
Authors: Anders Bergenfelz; Pia Lindblom; Birger Lindergård; Stig Valdemarsson; Johan Westerdahl Journal: World J Surg Date: 2003-04 Impact factor: 3.352
Authors: Hien Tran; Jacob S Grange; Beverley Adams-Huet; Fiemu E Nwariaku; Jennifer L Rabaglia; Stacey L Woodruff; Shelby A Holt; Naim M Maalouf Journal: J Clin Endocrinol Metab Date: 2014-03-31 Impact factor: 5.958
Authors: Elizabeth Grethen; Kathleen M Hill; RoseMarie Jones; Brenda M Cacucci; Christine E Gupta; Anthony Acton; Robert V Considine; Munro Peacock Journal: J Clin Endocrinol Metab Date: 2012-02-22 Impact factor: 5.958